


DeuterOncology NV Revenue
Biotechnology Research • Liège, Walloon Region, Belgium • 1-10 Employees
DeuterOncology NV revenue & valuation
| Annual revenue | $513,330 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $1,700,000 |
| Total funding | $6,100,000 |
Key Contact at DeuterOncology NV
Carol Walton
Bd & Strategy Advisor To Founder/Ceo
Company overview
| Headquarters | Clos Chanmurly 13, Liège, Walloon Region 4000, BE |
| Phone number | +3238877618 |
| Website | |
| NAICS | 541714 |
| Keywords | Drug Development, Deuterated Small Molecules, Met Kinase Inhibitor |
| Founded | 2020 |
| Employees | 1-10 |
| Socials |
DeuterOncology NV Email Formats
DeuterOncology NV uses 1 email format. The most common is {first initial}{last name} (e.g., jdoe@deuteroncology.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@deuteroncology.com | 100% |
About DeuterOncology NV
DeuterOncology NV is a Liege based clinical stage biotechnology company that was founded in September 2020 by Dr Timothy Perera. The company is currently focused on the clinical development of a highly selective brain penetrant, deuterated MET kinase inhibitor DO-2.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
DeuterOncology NV has 1 employees across 1 departments.
Departments
Number of employees
DeuterOncology NV Tech Stack
Discover the technologies and tools that power DeuterOncology NV's digital infrastructure, from frameworks to analytics platforms.
Security
JavaScript libraries
Web servers
Databases
Miscellaneous
Programming languages
Blogs
Maps
WordPress themes
Page builders
Miscellaneous
Performance
Frequently asked questions
4.8
40,000 users



